Nitric oxide (NO)' or closely related molecules account for the activity of endothelium-derived relaxing factor (1, 2) . This mediator stimulates guanylyl cyclase in smooth muscle cells leading to vascular relaxation (3) . Besides its vasodilatory effects, NO reportedly has many antiatherogenic properties. NO reduces platelet aggregability (4) , limits vascular smooth muscle cell proliferation (5, 6) , inhibits leukocyte adhesion to the endothelium (7, 8) , and prevents monocyte chemotaxis (9) . Chronic provision of L-arginine in the diets of hypercholesterolemic rabbits has been reported to improve endothelium-dependent vasodilation and to reduce the extent of atherosclerotic lesions (10) . Local leukocyte recruitment to the vessel wall is an early step in atherogenesis (11) , and endothelial-leukocyte adhesion molecules such as vascular cell adhesion molecule-i (VCAM-1), intercellular adhesion molecule-I (ICAM-1), and endothelial-leukocyte adhesion molecule-I (ELAM-1 or E-selectin) may facilitate recruitment of monocytes and lymphocytes to sites of lesion formation (12) (13) (14) (15) . Therefore, factors which modulate the expression of endothelial-leukocyte adhesion molecules and other endothelial-derived cytokines may be important in modulating lesion formation. This study sought to determine whether NO can limit endothelial activation by inhibiting adhesion molecule expression and monocyte adhesion.
Methods
Reagents. Sodium nitroprusside (SNP) was purchased from Elkins-Sinn (Cherry Hill, NJ), and 3-morpholino sydnonimine (SIN-1) was a gift from Dr. A. G. Cassella (Frankfurt, Germany). S-nitroso-glutathione (GSNO) was chemically synthesized from glutathione and sodium nitrite (Sigma Immunochemicals, St. Louis, MO) (16) . IL-la was obtained from Hoffmann-La Roche (Nutley, NJ). IL-1,3, TNFa, and IL-4 were purchased from Genzyme Corp. (Cambridge, MA). Escherichia coli lipopolysaccharide (LPS) was purchased from Sigma Immunochemicals. Cell-permeable superoxide dismutase (SOD) and catalase coupled to polyethylene glycol (PEG) were obtained from Sigma/Enzon (St. Louis, MO) (17) . Assays for IL-6 and IL-8 were measured according to commercially available enzyme immunoassay (EIA) kits (R & D Systems, Inc., Minneapolis, MN), assayed directly in human saphenous vein endothelial cell (HSVEC) supernates.
1. Abbreviations used in this paper: CAT, chloramphenicol acetyltransferase; EIA, enzyme immunoassay; GSNO, S-nitroso-glutathione; hpf, high-power field; HSVEC, human saphenous vein endothelial cells; ICAM-1, intercellular adhesion molecule-l; L-NAME, L-nitro-arginine methyl ester; L-NMA, L-N-monomethyl-arginine; NO, nitric oxide; SIN-1, 3-morpholino sydnonimine; SNP, sodium nitroprusside; VCAM-1, vascular cell adhesion molecule-1.
Cell culture. HSVEC were harvested enzymatically with type II collagenase 0.1% as described (18) and maintained in medium 199 (GIBCO BRL, Gaithersburg, MD), containing Hepes (25 mmol/liter), heparin (1%), endothelial cell growth factor (50 Ag/m1l), L-glutamine (1%), antibiotics, and 5% fetal calf serum (Hyclone Laboratories, Logan, UT). Once grown to confluence, the cells were replated on low pyrogen fibronectin (1.5 tig/cm2) at 20,000 cells/cm2. HSVEC isolated by these techniques form a confluent monolayer of polygonal cells and express von Willebrand factor as determined by their content of specific mRNA and immunoreactive protein (18) . Cell number was assessed after trypsinization in a Neubauer hemocytometer (VWR Scientific Corp., Philadelphia, PA). Cellular viability was assessed by Trypan blue exclusion. Bovine aortic endothelial cells (106/100-mm culture dish, grown in DME with 5% heat-inactivated fetal calf serum) were used within passage 3 for transfection experiments.
Detection ofcell surface molecules. Assay of cell surface molecules was carried out after treatment with cytokines and NO donors for 24 h. The expression of adhesion molecules was determined by cell surface EIA or flow cytometry using mouse anti-human monoclonal antibodies against VCAM-1 (antibody El/6), E-selectin (Ab H18/7), ICAM-1 (Ab HU 5/3), MHC-I (W6/32) (19), or a constitutive and non-cytokine-inducible endothelial cell antigen (El/1) (20) . These last two endothelial surface molecules share a high level of basal constitutive expression, although MHC-I antigen (Ag), at variance from El/I Ag, shows some degree of inducibility by cytokines. EIA were carried out by incubating monolayers first with saturating concentrations of specific monoclonal antibodies against the target molecule, then with biotinylated goat anti-mouse IgG (Vector Labs, Inc., Burlingame, CA), and finally with streptavidin-alkaline phosphatase (Zymed Laboratories, Inc., South San Francisco, CA). Layers were washed three times between each incubation step, and integrity of the monolayer was monitored by phase-contrast microscopy. The surface expression of each protein was quantified spectrophotometrically, reading the optical density of the wells (410 nm) 15-60 min after the addition of a chromogenic substrate (para-nitrophenylphosphate), as described (19) .
Flow cytometric analysis of adhesion molecules was performed by suspending HSVEC in Hanks' buffered saline solution containing 3 mmol/liter EDTA and incubating the cells with specific primary antibody for 30 min at 4°C. After washing, the cells are then exposed to goat anti-mouse F(ab')2 labeled with fluorescein-isothiocyanate (Caltag Laboratories, San Francisco, CA) at 4°C. After further washing, the cell suspension was passed through a FACScan6 analyzer (BectonDickinson Immunocytometry Systems, Mountain View, CA). Results were plotted as intensity of fluorescence (arbitrary units, on logarithmic scale, on the abscissa) versus cell number (on the ordinate, total cells counted, 104 for each condition).
Assessment of total protein synthesis. HSVEC were cultured in 96-well plates and stimulated with IL-la in the presence and absence of NO donors. After 24 h, the total cell-associated protein content was assessed by the amido black assay, as previously described (21 For the adhesion assays, HSVEC were grown to confluency in 6-well tissue culture plates, after which IL-4 (50 ng/ml) or IL-la (10 ng/ ml) was added for an additional 24 h, in order to induce the expression of VCAM-1, in the presence or absence of GSNO (0.2 X IO-3 mol/liter). For control, some monolayers were treated with a mouse anti-human monoclonal antibody (El /6) against VCAM-1. The adhesion assay was performed by adding 1 ml of the concentrated monocytes or U937 cell suspension to each monolayer under rotating conditions (63 rpm) at 21°C. After 10 min, nonadhering cells were removed by gentle washing with medium 199, and monolayers were fixed with 1% paraformaldehyde. The number of adherent cells was determined by counting six different high-power fields (hpf) using an ocular grid and a X 20 objective (0.16 mm2/field). Fields for counting adherent leukocytes were randomly located at half-radius distance from the center of the monolayers.
Northern analysis. HSVEC RNA was isolated by ultracentrifugation through CsCl (25) . Total RNA (20 (26) . Linearized plasmids (1 4g) were immobilized on nylon membranes, hybridized to radiolabeled transcripts ( -5-8 x 107 cpm/ml) at 45°C for 48 h in hybridization buffer containing 50% formamide, 5 x SSC, 2.5 X Denhardt's Solution, 25 mM sodium phosphate buffer (pH 6.5), 0.1% SDS, and 250 mg/ml salmon sperm DNA, and washed in 1 x SSC/0.1% SDS at 650C before autoradiography.
Transfections. The human VCAM-1 promoter constructs containing the chloramphenicol acetyltransferase (CAT) reporter were described previously by Neish et al. (27) (28) . As an internal control for transfection efficiency, pRSV./3GAL plasmid (10 /ig) was cotransfected in all experiments. Preliminary results using 3-galactosidase staining indicate that cellular transfection efficiency was -12-15%. Cells (60-70% confluent) were stimulated 48 h after transfection with IL-la ( 10 ng/ml) and TNFa (10 ng/ml) (alone or in combination with GSNO [0.2 mmol/liter]), and cellular extracts were prepared 12 h later using lysis buffer (100 mg/ml leupeptin, 50 pg/ml aprotinin, 0.1 mM PMSF, 5 mM EDTA, 5 mM EGTA, 100 mM NaCl, 5 mM Tris-HCl, pH 7.4) and one freeze-thaw cycle. The cellular extracts were centrifuged at 12,000 g for 10 min, and the supernatant was subjected to CAT and /-galactosidase assay.
CAT assays. CAT activity was determined by incubating the super- (30) . The normalized CAT activity was calculated as the ratio of CAT to /3-galactosidase activity.
The relative CAT activity was standardized to the normalized FO.CAT activity having a value of 100. Each experiment was performed three times in duplicate and all experiments included both positive (highly expressed pSV40.CAT) and negative (promoterless po.CAT) controls. Electrophoretic mobility shift assay. Nuclear extracts were prepared as described (31) . The NF-KB oligonucleotide (CCTGGGTTTCCC-CTTGAAGGGATTTCCCTCC) spanning the two tandem KB sites in the human VCAM-1 promoter (27) mol/liter) caused a 35-55% (range) reduction of IL-la-stimulated VCAM-l expression after 24 h, but had no effect on the surface expression of two constitutive endothelial surface proteins, El/1 and MHC-I (Table I) .
Flow cytometric analysis also demonstrated inhibition of VCAM-1 expression by GSNO (Fig. 2) . Unstimulated HSVEC expressed little or no VCAM-1, as the distribution of fluorescence intensity compared with cell number in such conditions (Fig. 2 A) overlapped that obtained with a control preimmune serum (not shown). Treatment with GSNO did not affect basal VCAM-1 surface expression (Fig. 2 B) . Stimulation of HSVEC with IL-la shifted the cell population to the right and widened its distribution (Fig. 2 C) , indicating increased VCAM-1 expression in the cell population. Compared with IL-la alone, GSNO, when added with 11L-la, shifted the distribution leftward, decreasing both its median value and its dispersion (Fig.  2 D) . These results indicate that, under GSNO treatment, fewer cells expressed VCAM-1 and, on the average, each cell did so to a lesser extent. Controls for flow cytometry included the use of an antibody against a constitutive and non-cytokineinducible endothelial antigen (Ab El/1), with which all distributions appeared uniformly shifted to the right, and a preimmune serum (results not shown), which yielded distributions similar to those shown in Fig. 2, A and B. GSNO inhibits other cytokine-stimulated cell-associated and secreted molecules. We investigated the effect of GSNO on other cytokine-inducible endothelial proteins, including two other endothelial-leukocyte adhesion molecules, E-selectin and ICAM-1, and two secretable proteins, IL-6 and 11L-8. GSNO inhibited cytokine-induced surface expression or secretion of each of these proteins (Fig. 3 and Table II ). In comparative experiments, inhibition of inducible ICAM-1 expression, however, was negligible compared with that of either VCAM-1 or E-selectin (Fig. 3) . GSNO did not affect basal (constitutive) ICAM-1 expression. Inhibition of IL-8 also was lower than for IL-6 (Table II) . These experiments indicate that NO selectively decreases production of certain cytokine-induced molecules in endothelial cells.
GSNO inhibits VCAM-J expression in response to other cytokines. We assessed and compared the inhibition of VCAM-1 expression by GSNO in response to a variety of structurally unrelated agonists such as IL-1p3, IL-4, TNFa, and LPS. GSNO inhibited VCAM-1 expression to virtually the same extent with each stimulus tested (Fig. 4) , independent of the relative potency of the stimulus.
Maximum inhibition of VCAM-J by GSNO (Fig. 5, left) . Exposure of HSVEC to IL-la (10 ng/ml, 24 h) increased monocyte adhesion substantially (Fig.   5, middle) . Treatment of HSVEC with GSNO (0.2 X 10-3 mol/liter) inhibited IL-la-induced monocyte adhesion by 61% (Fig. 5, right) . 11-4 yielded qualitatively similar results (baseline: 2±1 cells/hpf; IL-4 50 ng/ml: 27±5 cells/hpf; 11L-4 + GSNO: 8±3 cells/hpf, corresponding to a 70% inhibition). Similar effects were also observed for U937 cell adhesion (not Table II GSNO. Inhibition of VCAM-J expression by GSNO is not mediated by cGMP. To test whether cGMP mediates the inhibitory effect of NO donors on VCAM-1 levels, we tested the effects on ILla-stimulated VCAM-l expression of two membrane-permeable cGMP analogues, dibutyryl cGMP and 8-bromo cGMP, in a range of concentrations from 10-8 to IO-5 mol/liter. We chose these concentrations because they did not produce toxic effects on endothelial cells (as judged by morphology, Trypan blue exclusion, and cell counting) during the 24-h incubation and because they encompass concentrations able to mimic vasodilatory and antiplatelet effects of NO (3). Neither agent reduced IL-la -stimulated VCAM expression (Fig. 6 A) . Furthermore, there was no trend toward any decline over the entire range of concentrations explored. Preliminary studies using metabolic labeling with [ h. n = 16 for each different condition. * Statistically significant differences (P < 0.05) between groups joined by the horizontal lines.
points after IL-la addition (Fig. 6 A) mRNA expression over a range of IL-la concentrations (0.1-100 ng/ml) (Fig. 6 B) . Inhibition of endogenous NO with L-N-monomethyl-arginine (L-NMA; 1 X i0' mol/liter) augmented the expression of VCAM-1 mRNA in unstimulated cells, but had lesser effect on VCAM-1 mRNA expression in TNFa-stimulated cells (Fig. 6 C) . In addition, the induction of VCAM-1 mRNA expression by TNFa was blunted by cellpermeable PEG-catalase, and to a lesser extent, PEG-SOD, suggesting involvement of hydrogen peroxide to a greater extent than superoxide anion in TN'Fa-induced modulation of VCAM-1 mRNA (Fig. 6 D) . NO decreases cytokine-stimulated VCAM-1 transcription. In the presence of actinomycin D, GSNO did not significantly affect the half-life of VCAM-1 mRNA (5.2±+1.8 h vs. 4.7±1.5 h, P = NS) indicating that the inhibitory effect of NO on VCAM-1 expression occurs at the level of transcription (Fig.  7 A) . Nuclear run-on assays demonstrated a transcriptional effect of NO on VCAM-1 expression (Fig. 7 B) . Transcription IL-la + GSNO 165±47 of the 3-tubulin gene served as an internal control, and lack of hybridization to the insertless vector, pGEM, established specificity (data not shown).
To localize possible sites of inhibition on the VCAM-1 promoter by NO, we performed transfection studies with various deletional promoter reporter CAT constructs (Fig. 8 A) using bovine aortic endothelial cells which yielded a higher transfection efficiency than human endothelial cells. The promoterless po.CAT and the highly expressed pSV40.CAT served as negative and positive controls in the reporter assays. The promoterless po.CAT and pF4.CAT produced essentially no relative CAT activity either basally or after stimulation with TNFa (Fig.  8 B) . Stimulation with TNFa of transfectants containing the fully functional VCAM-1 promoter, FO, increased relative CAT activity from 101±16 to 1,240±235. Cotreatment with GSNO resulted in a 76% decrease in relative CAT activity (300±63), indicating that NO can inhibit TNFa-stimulated VCAM-1 promoter activity.
Transfection studies were also performed using pF3.CAT, a deletional VCAM-I promoter construct containing two tandem NF-KB sites, but no AP-1 and GATA sites (Fig. 8 B) . Stimulation of pF3.CAT transfectants with IL-la and TNFa increased relative CAT activity from 73±23 to 474±52, suggesting that binding of NF-KB may be involved in the induction of VCAM-1 transcriptional activity, albeit at a significantly lower level compared with pFO.CAT. Cotreatment with GSNO reduced the relative CAT activity of pF3.CAT transfectants to basal levels (139±51). NO inhibits NF-KB activation. To determine whether NO inhibits NF-KB activation, electrophoretic mobility shift assays were performed using radiolabeled oligonucleotide corresponding to the two tandem KB sites in the VCAM-1 promoter (Fig.  9) . GSNO (0.2 x 10-3 mol/liter) decreased the amount of shifted complex induced by TNFa, indicating that NO inhibits the activation of NF-KB. The shifted complexes were specific for NF-KB since they were supershifted in the presence of antibodies to NF-KB subunits and disappeared with excess unlabeled oligonucleotide. In addition, neither 8-bromo-cGMP (1 X 10-3 mol/liter), glutathione (0.2 x 10-3 mol/liter), nor nitrite (0.2 x 10-3 mol/liter) had any effects on activation of NF-KB (data not shown).
Discussion
We have shown that NO can reduce cytokine-induced expression of a number of pathophysiologically relevant effector molecules characteristic of endothelial activation. Upon appropriate stimulation, the endothelium exhibits increased adhesiveness for monocytes, lymphocytes, and granulocytes. Increased or newly induced expression of endothelial-leukocyte adhesion molecules (e.g., ICAM-1, VCAM-1, and E-selectin) mediates such enhanced adhesive interactions ( 13, 14, 33, 34) . The secre- tion of inflammatory cytokines (IL-6) (34) and of leukocytespecific chemoattractants, such as IL-8 and MCP-1, also likely contributes to leukocyte recruitment during inflammatory responses in vivo (23, 35) . NO significantly inhibits the expression of VCAM-1, E-selectin, and IL-6, and, to a lesser extent, IL-8 and ICAM-1. Three structurally different NO donors inhibited cytokine-induced VCAM-1 expression and concomitantly reduced monocyte adhesion to cultured endothelial monolayers. The lack of effects of nitrite or glutathione renders it unlikely that our findings were due to mediators other than NO. The physiologic relevance of NO's inhibitory effects is supported by the finding that inhibition of endogenous NO by L-NMA can also lead to the induction of VCAM-1 expression, albeit to a lesser degree compared with cytokine activation. This result suggests that endogenous endothelial NO production tonically inhibits VCAM-1 expression in endothelial cell cultures. Because induction with cytokines results in much higher levels of VCAM-1 expression compared with L-NMA, L-NMA produced only a small augmentation of VCAM-1 expression in cytokine-induced endothelial cells. These results agree with our finding that endogenous levels of NO are not sufficient in limiting cytokine-induced VCAM-1 expression. However, at sites of inflammation, several cell types such as macrophages and vascular smooth muscle cells, have the capacity to generate 100-fold higher concentrations of inducible NO at levels comparable with the amount of NO released by GSNO in our study (36, 37 (44) .
The ability of NO to inhibit monocyte adhesion to endothelium. is consistent with previous observations (7, 8 Kubes and collaborators (7) also showed that such inhibitors increase leukocyte (mostly neutrophil) adhesion to mesenteric venules. They also showed that increased expression of CDllb/CD18 on the leukocyte surface could not account for L-NAME's effect (7) . Other in vivo studies by Kurose and (46) . Our in vitro study provides a link between NO production and monocyte adhesion and offers clues as to the mechanism of such an effect. Local generation of sufficiently high amounts of NO by either endothelial cells themselves or by other neighboring cells in response to inflammatory stimuli could provide a homeostatic regulation of monocyte adhesion under physiological conditions within the vessel wall. Endothelial dysfunction resulting in reduced level of NO activity can lead not only to an imbalance in vascular tone, favoring acute vasoconstriction ( 1, 2), but can also impair an endogenous negative feedback loop that limits VCAM-1 expression, leukocyte adhesion, and atherogenesis.
In summary, we have shown that exogenous as well as endogenous sources of NO can limit the degree of endothelial activation. The ability of NO to inhibit the expression of endothelial-leukocyte adhesion molecules and certain proinflammatory cytokines makes it a potentially important regulator of inflammatory trafficking within the vessel wall.
